A new study looked into the various types of subjective experiences produced by five types of psychedelic drugs. Using computer algorithms, the researchers conducted an analysis of thousands of reports on the effects of psychedelic substances that were anonymously published.
Research has shown that psychedelic substances, including psilocybin and MDMA, possess the potential to treat psychiatric conditions such as PTSD and depression. While various studies have shown that these drugs cause changes in an individual’s consciousness and perception, minimal research has been conducted quantifying the experiences linked to the consumption of these drugs.
Adrian Hase, a postdoctoral researcher at the University of Fribourg and the study’s author, revealed that he was interested in the promising findings from studies that assessed psychedelic treatments for different mental health condition. These treatments were used to treat patients who hadn’t responded to standard treatments.
The researchers carried out basic research into the effects of these substances, with a focus on psychopathology and stress. For their study, the academics analyzed the content of more than 2,900 online reports sourced from the Erowid experience vault, using software known as the Linguistic Inquiry and Word Count. The Erowid Center is a not-for-profit educational organization that provides the Erowid experience vault.
The sample comprised of reports about antidepressants, ayahuasca, ketamine, DMT, LSD and magic mushrooms.
In an interview, Hase stated that the group observed differences in how individuals wrote about their experiences with psychedelic substances, noting that this mainly depended on the substance used. He explained that the language in the substance report groups that they analyzed was different from the language from the control reports, which described the use of antidepressant drugs.
The researchers also found differences between different substances, noting that the differences were found on language outcomes associated with mystical experience, psychedelic experience, analytical thinking, cognitive processes and affective processes.
For instance, reports on DMT and ayahuasca contained more language related to analytical thinking and fewer words associated with emotions, in comparison to other substances. Contrastingly, reports on MDMA contained less language linked to analytical thinking and more emotional language.
In their report, the researchers noted that they hoped their study would contribute to harm reduction and education adding that they did not promote the use of illicit drugs. The researchers plan to replicate their findings in an experiment in a controlled setting where participants will have the substances administered.
The study’s findings were reported in the “Psychopharmacology Journal.” Other researchers who were part of the study include Gregor Hasler, Verena Limbach and Max Erdmann.
It is encouraging to see so many entities, such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), engaged in psychedelics-focused R&D activities aimed at bringing to market formulations that will address the unmet needs of patients suffering from mental health conditions and other ailments.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…